Founded by entrepreneurs with deep sector experience, a venture capital firm headquartered in Western Europe, focused on novel therapeutics. The firm is an early-stage investor, investing from seed through late stage pre-clinical. The firm will typically stay with the asset until after clinical proof-of-concept, at which point they will exit. The firm is currently investing from a Europe-focused fund, and plans to invest in more USA-based companies with their next fund. The firm makes initial investments of $3M – $5M in equity and occasionally convertible loans. The firm can make follow-on investments, up to a total of $15-20M per investment.
The firm is solely focused on therapeutics. The firm is indication- and modality- agnostic. The firm’s larger focus is on stage of development and that there is a large unmet need with high commercial value.
The firm will both lead and co-invest. They do not have strict team requirements, though prefer for teams with previous experience.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment